MedTrace Logo

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

NCT00017680 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2008-06-09

No results posted yet for this study

Summary

OBJECTIVES: I. Determine the response, disease-free survival, and overall survival of patients with primary light chain amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

II. Determine the toxicity of this regimen in these patients.

Conditions

  • Amyloidosis

Interventions

DRUG

Melphalan

100 mg/m2 twice a day from Days -2 and -1 as induction therapy

PROCEDURE

Autologous Stem Cell Transplantation

Bone marrow and peripheral blood stem cells harvested

Sponsors & Collaborators

  • Herbert Irving Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Charles S. Hesdorffer · Herbert Irving Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Primary Completion
2004-04-30
Completion
2004-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00017680 on ClinicalTrials.gov